Join the Keytruda group to help and get support from people like you.
Keytruda News
Outcomes With Immune Checkpoint Inhibitors Similar for Older, Younger Patients
TUESDAY, April 29, 2025 – Patients with cancer aged 65 years and older receiving immune checkpoint inhibitors (ICIs) derive similar clinical outcomes as younger patients, according to a study...
Immune Therapy Works As Well In Senior Cancer Patients As In Younger Adults
TUESDAY, April 22, 2025 — It’s well-known that a person’s immune system wears down over time, becoming less effective as folks progress through middle age and become seniors. But that doesn’t appear t...
Durable Disease Control Possible After Stopping Immune Checkpoint Inhibitors in NSCLC
TUESDAY, April 22, 2025 – Prolonged disease control can be maintained for patients with advanced non-small cell lung cancer (NSCLC) who discontinue immune checkpoint inhibitors (ICIs) for...
Lung Cancer Remains At Bay Long After Immune Therapy Is Dropped
MONDAY, April 21, 2025 — Immunotherapy might help keep lung cancer at bay for months or even years after the treatment has been abandoned due to side effects, a new study says. Immune checkpoint i...
FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1)
On March 19, 2025, the Food and Drug Administration granted traditional approval to pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the...
TACE + Lenvatinib, Pembrolizumab Tied to Improved Survival in Unresectable Liver Cancer
THURSDAY, Jan. 16, 2025 – For patients with unresectable, nonmetastatic hepatocellular carcinoma, transarterial chemoembolization (TACE) with the addition of lenvatinib and pembrolizumab is...
So, Who Benefits From New Cancer Drugs?
THURSDAY, Jan. 16, 2025 – Cutting-edge targeted therapies are pushing back the line between life and death for cancer patients. However, these targeted cancer drugs frequently aren’t benefitting m...
Adding Pembrolizumab Ups Survival in Stage III Undifferentiated Sarcoma
THURSDAY, Nov. 21, 2024 – For patients with stage III undifferentiated pleomorphic sarcoma or dedifferentiated or pleomorphic liposarcoma of the extremity and limb girdles, adding pembrolizumab to...
Science Reveals Why Cancer Immunotherapies Can Sometimes Harm the Heart
FRIDAY, Nov. 8, 2024 – Researchers think they’ve figured out why cancer treatments that harness a person’s immune system to fight a tumor can cause heart damage in rare instances. Further, what the...
Pembrolizumab Aids Survival With High-Risk Endometrial Cancer
MONDAY, Oct. 21, 2024 – Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after surgery with curative intent, according to a study...
What You Need to Know After a Breast Cancer Diagnosis
SATURDAY, Oct. 5, 2024 – Breast cancer strikes 1 in 8 women in the United States, but being diagnosed with the disease can still make you feel alone. To cope with such devastating news, breast...
FDA Approves Merck’s Keytruda (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
RAHWAY, N.J.--(BUSINESS WIRE) September 18, 2024 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved...
Adjuvant Pembrolizumab Improves Survival in Muscle-Invasive Urothelial Cancer
FRIDAY, Sept. 20, 2024 – Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk muscle-invasive urothelial carcinoma after radical...
Pembrolizumab + Chemo Beneficial for Early-Stage Triple-Negative Breast Cancer
THURSDAY, Sept. 19, 2024 – For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab yields a significant...
Post-Op Keytruda Boosts Bladder Cancer Outcomes
WEDNESDAY, Sept. 18, 2024 – When given after organ-removal surgery, Keytruda brings patients battling advanced bladder cancers more time cancer-free, a new trial finds. Folks with "high-risk"...
Further information
Related condition support groups
Breast Cancer, Colorectal Cancer, Endometrial Cancer, Gastric Cancer, Hepatocellular Carcinoma, Hodgkin's Lymphoma, Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma